Understanding the GOLD 2011 Strategy as applied to a real-world COPD population

Respiratory Medicine

Volumn 108, Issue 5, 2014, Pages 729-736

  Vestbo, Jørgen ^a,b   Vogelmeier, Claus ^c   Small, Mark ^d   Higgins, Victoria ^d  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY HOSPITAL MARBURG   (Germany)

^d ADELPHI REAL WORLD   (United Kingdom)

Author keywords

Bronchodilators; Comorbidities; COPD; Exacerbations; GOLD document; Inhaled corticosteroids

Indexed keywords

ANTIBIOTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG; BRONCHODILATING AGENT; GLUCOCORTICOID;

ADULT; AGED; ANTIBIOTIC THERAPY; ANXIETY; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTROLLED STUDY; COPD ASSESSMENT QUESTIONNAIRE; CROSS-SECTIONAL STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE EXACERBATION; DISEASE SEVERITY; EMPLOYMENT STATUS; EUROPE; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GENERAL PRACTITIONER; GOLD 2011 STRATEGY; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; LOW RISK POPULATION; LUNG FUNCTION; MAJOR CLINICAL STUDY; MEDICAL HISTORY; MONOTHERAPY; OBSERVATIONAL STUDY; PATIENT CARE; PREVALENCE; PRIORITY JOURNAL; PULMONOLOGIST; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SLEEP DISORDERED BREATHING; SMOKING; SPIROMETRY; TREATMENT DURATION; UNITED STATES; CLINICAL TRIAL; DISEASE COURSE; DRUG UTILIZATION; HEALTH CARE SURVEY; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; PROFESSIONAL PRACTICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BRONCHODILATOR AGENTS; COMORBIDITY; CROSS-SECTIONAL STUDIES; DISEASE PROGRESSION; DRUG UTILIZATION; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HEALTH CARE SURVEYS; HUMANS; MIDDLE AGED; PROFESSIONAL PRACTICE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84899491531     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2014.03.002     Document Type: Article

References (26)

1. J. Vestbo, S.S. Hurd, A.G. Agusti, P.W. Jones, C. Vogelmeier, and A. Anzueto et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary Am J Respir Crit Care Med 187 2013 347 365
2. M. Cazzola, W. Macnee, F.J. Martinez, K.F. Rabe, L.G. Franciosi, and P.J. Barnes et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers Eur Respir J 31 2008 416 469
3. T. Glaab, C. Vogelmeier, and R. Buhl Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations Respir Res 11 2010 79
4. N.F. Schlecht, K. Schwartzman, and J. Bourbeau Dyspnea as clinical indicator in patients with chronic obstructive pulmonary disease Chron Respir Dis 2 2005 183 191 (Pubitemid 41527260)
5. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2011). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011 revision. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available at: http://www.goldcopd.org/uploads/ users/files/GOLD-Report-2011-Jan21.pdf [last accessed 10.09.13].
6. M.K. Han, H. Mullerova, D. Curran-Everett, M.T. Dransfield, G.R. Washko, and E.A. Regan et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study Lancet Respir Med 1 2013 43 50
7. P. Lange, J.L. Marott, J. Vestbo, K.R. Olsen, T.S. Ingebrigtsen, and M. Dahl et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population Am J Respir Crit Care Med 186 2012 975 981
8. A. Agusti, L.D. Edwards, B. Celli, W. Macnee, P.M. Calverley, and H. Mullerova et al. Characteristics, stability and outcomes of the GOLD 2011 COPD groups in the eclipse cohort Eur Respir J 42 2013 636 646
9. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2013). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013. Available at: http://www.goldcopd. org/uploads/users/files/GOLD-Report-2013-Feb20.pdf [last accessed 14.09.13].
10. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2014). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2014. Available at: http://www.goldcopd. org/uploads/users/files/GOLD-Report-2014.pdf [last accessed 21.01.14].
11. Global Initiative for Chronic Obstructive Lung Disease (GOLD 2010) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2010 Global Initiative for Chronic Obstructive Lung Disease (GOLD) Available at: http://www.goldcopd.org/ [last accessed 14.09.13]
12. P. Anderson, M. Benford, N. Harris, M. Karavali, and J. Piercy Real-world physician and patient behaviour across countries: disease-specific programmes - a means to understand Curr Med Res Opin 24 2008 3063 3072
13. P.W. Jones, G. Harding, P. Berry, I. Wiklund, W.H. Chen, and L.N. Kline Development and first validation of the COPD assessment test Eur Respir J 34 2009 648 654
14. J.C. Bestall, E.A. Paul, R. Garrod, R. Garnham, P.W. Jones, and J.A. Wedzicha Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease Thorax 54 1999 581 586 (Pubitemid 29296676)
15. S. Suissa, S. Dell'Aniello, and P. Ernst Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality Thorax 67 2012 957 963
16. S. Suissa, and P.J. Barnes Inhaled corticosteroids in COPD: the case against Eur Respir J 34 2009 13 16
17. D.P. Tashkin, B. Celli, S. Senn, D. Burkhart, S. Kesten, and S. Menjoge et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
18. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Molken, and K.M. Beeh et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD N Engl J Med 364 2011 1093 1103
19. F.M. Franssen, M.A. Spruit, and E.F. Wouters Determinants of polypharmacy and compliance with GOLD guidelines in patients with chronic obstructive pulmonary disease Int J Chron Obstruct Pulmon Dis 6 2011 493 501
20. A. Jochmann, F. Neubauer, D. Miedinger, S. Schafroth, M. Tamm, and J.D. Leuppi General practitioner's adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort Study Swiss Med Wkly 140 2010 w13053
21. J. Seaman, A.C. Leonard, and R.J. Panos Health care utilization history, GOLD guidelines, and respiratory medication prescriptions in patients with COPD Int J Chron Obstruct Pulmon Dis 5 2010 89 97
22. K. Fitch, K. Iwasaki, B. Pyenson, C. Plauschinat, and J. Zhang Variation in adherence with Global Initiative for Chronic Obstructive Lung Disease (GOLD) drug therapy guidelines: a retrospective actuarial claims data analysis Curr Med Res Opin 27 2011 1425 1429
23. J.M. Marin, I. Alfageme, P. Almagro, C. Casanova, C. Esteban, and J.J. Soler-Cataluña et al. Multicomponent indices to predict survival in COPD: the COllaborative COhorts to assess multicomponent indices of COPD in Spain-COCOMICS study Eur Respir J 42 2013 323 332
24. M.K. Han, P. Lange, A. Anzueto, F.J. Martinez, and P.W. Jones Authors' reply to: GOLD COPD categories are not fit for purpose in primary care Lancet Respir Med 1 2013 e17 e18
25. J.R. Hurst, J. Vestbo, A. Anzueto, N. Locantore, H. Mullerova, and R. Tal-Singer et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease N Engl J Med 363 2010 1128 1138
26. M. Thomsen, T.S. Ingebrigtsen, J.L. Marott, M. Dahl, P. Lange, and J. Vestbo et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease J Am Med Assoc 309 2013 2353 2361